{"nctId":"NCT05405244","briefTitle":"Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM","startDateStruct":{"date":"2017-09-19","type":"ACTUAL"},"conditions":["Overweight and Obesity","Eating Behavior"],"count":55,"armGroups":[{"label":"Bromocriptine, then Placebo","type":"OTHER","interventionNames":["Drug: Placebo","Drug: Bromocriptine-QR"]},{"label":"Placebo, then Bromocriptine","type":"OTHER","interventionNames":["Drug: Placebo","Drug: Bromocriptine-QR"]}],"interventions":[{"name":"Placebo","otherNames":["placebo (calcium supplement)"]},{"name":"Bromocriptine-QR","otherNames":["quick-release (QR) bromocriptine (cycloset)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Baseline BMI between 25 and 35\n\nExclusion Criteria:\n\n* Individuals with current fMRI contraindications (e.g., metal implants, braces)\n* Probable current Axis I psychopathology (e.g., major depression disorder, panic disorder, generalized anxiety disorder, bipolar disorder)\n* Habitual use of cigarettes or illicit drugs\n* Pregnancy or breastfeeding\n* Diagnosis of serious medical problems (e.g., diabetes, cardiovascular disease, stroke)\n* Current weight loss dieting and/or weight fluctuations great than 10 lbs in the previous 6 weeks\n* Do not consume dairy\n* Allergy to bromocriptine, dairy, and nuts","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"35 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ad Libitum Food and Beverage Intake (g)","description":"Ad libitum food intake of highly-palatable snacks is assessed during each intervention arm. Participants are left alone for 25 minutes to eat as much as they want from a selection of snacks (M\\&Ms, Skittles, Doritos, cheddar popcorn) and a chocolate milkshake. Both snacks and milkshake are pre- and post-weighed to determine ad libitum food intake.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.5","spread":"58.5"},{"groupId":"OG001","value":"81.9","spread":"55.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.9","spread":"61.2"},{"groupId":"OG001","value":"33.6","spread":"66.1"}]}]}]},{"type":"PRIMARY","title":"Hedonic Ratings of Food as Measured by a Visual Analog Scale","description":"Testing the effects of the drug on hedonic ratings (pleasantness, desire to consume) of milkshake and snacks on a scale from -100 to 100.\n\nPleasantness was assessed by asking 'How pleasant is this taste?', with responses ranging from -100 (most unpleasant imaginable) to 100 (most pleasant imaginable).\n\nDesire to consume was assessed by asking 'How much would you want to eat/drink this?', with responses ranging from -100 (least desirable imaginable) to 100 (most desirable imaginable).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6","spread":"15.8"},{"groupId":"OG001","value":"32.2","spread":"15.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":"22.4"},{"groupId":"OG001","value":"14.6","spread":"22.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":"34.3"},{"groupId":"OG001","value":"32.4","spread":"15.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"40.2"},{"groupId":"OG001","value":"-5.6","spread":"41.2"}]}]}]},{"type":"PRIMARY","title":"Change in Voxel-wise Blood Oxygen Level-Dependent (BOLD) Brain Activation in Response to Milkshake Anticipation and Receipt vs. Water","description":"The fMRI paradigm assesses evoked BOLD response to cue-elicited anticipation and receipt of a milkshake and water. A region-of-interest (ROI) approach is used to assess changes in BOLD signal in the striatum. The striatal response is assessed for the two contrasts of interest: milkshake\\>h2o anticipation and milkshake\\>h2o receipt. Positive values reflect a higher striatal BOLD activation for the milkshake; negative reflects a higher striatal BOLD activation for the water. Parameter estimates of the relative BOLD response to each of these contrasts are extracted and compared between the two arms.\n\nThe paradigm has 64 trials and each trial starts with the presentation of a cue for 1s signaling the impending delivery of either 3 mL of highly palatable milkshake or a control water solution over a period of 6s. Taste delivery is followed by a wait period and rinse (tasteless solution). The next trial begins after a 1-9s jitter. Order of milkshake and water trials is pseudo-randomized.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.24","spread":"180.43"},{"groupId":"OG001","value":"15.66","spread":"208.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.32","spread":"57.68"},{"groupId":"OG001","value":"3.75","spread":"66.03"}]}]}]},{"type":"SECONDARY","title":"Ad Libitum Food and Milkshake Intake (g) by TaqIA Allele Status (A1 vs. A2/A2)","description":"Testing the drug by gene (TaqIA) interaction on ad libitum food intake (g).The presence of the high-risk A1 allele of the TaqIA polymorphism (rs1800497) in the DRD2 gene was determined from saliva samples and is compared to the A2/A2 variant.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":"64.3"},{"groupId":"OG001","value":"70.7","spread":"50.2"},{"groupId":"OG002","value":"75.2","spread":"46.1"},{"groupId":"OG003","value":"91.4","spread":"67.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":"57.9"},{"groupId":"OG001","value":"23.3","spread":"67.2"},{"groupId":"OG002","value":"35.5","spread":"66.7"},{"groupId":"OG003","value":"30.9","spread":"67.1"}]}]}]},{"type":"SECONDARY","title":"Hedonic Ratings of Milkshake Pleasantness and Desire as Measured by a Visual Analog Scale by TaqIA Allele Status (A1 vs. A2/A2)","description":"Testing the drug by gene (TaqIA) interaction on hedonic ratings (pleasantness, desire to consume) of milkshake on a scale from -100 to 100. Testing the drug by gene (TaqIA) interaction on ad libitum milkshake (g). The presence of the high-risk A1 allele of the TaqIA polymorphism (rs1800497) in the DRD2 gene was determined from saliva samples and is compared to the A2/A2 variant.\n\nPleasantness was assessed by asking 'How pleasant is this taste?', with responses ranging from -100 (most unpleasant imaginable) to 100 (most pleasant imaginable).\n\nDesire to consume was assessed by asking 'How much would you want to eat/drink this?', with responses ranging from -100 (least desirable imaginable) to 100 (most desirable imaginable).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":"2.5"},{"groupId":"OG001","value":"15.1","spread":"38.8"},{"groupId":"OG002","value":"29.9","spread":"29.7"},{"groupId":"OG003","value":"12.2","spread":"27.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"38.8"},{"groupId":"OG001","value":"-18.1","spread":"40.3"},{"groupId":"OG002","value":"16.6","spread":"20.9"},{"groupId":"OG003","value":"-21.5","spread":"36.2"}]}]}]},{"type":"SECONDARY","title":"Change in Voxel-wise Blood Oxygen Level-Dependent (BOLD) Brain Activation in Response to Milkshake Anticipation and Receipt vs. Water by TaqIA Allele Status (A1 vs. A2/A2)","description":"The fMRI paradigm assesses evoked BOLD response to cue-elicited anticipation and receipt of a milkshake and water. A region-of-interest (ROI) approach is used to assess changes in BOLD signal in the striatum. The striatal response is assessed for the two contrasts of interest: milkshake\\>h2o anticipation and milkshake\\>h2o receipt. Positive values reflect a higher striatal BOLD activation for the milkshake; negative reflects a higher striatal BOLD activation for the water. Parameter estimates of the relative BOLD response to these contrasts are extracted and used to test the drug by gene (TaqIA) interaction.\n\nThe paradigm has 64 trials and each trial starts with the presentation of a cue signaling the impending delivery of either 3 mL of highly palatable milkshake or a control water solution over a 6s period. Taste delivery is followed by a wait period and rinse (tasteless solution). The next trial begins after a 1-9s jitter. Order of milkshake and water trials is pseudo-randomized.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.14","spread":"139.86"},{"groupId":"OG001","value":"-8.44","spread":"209.51"},{"groupId":"OG002","value":"71.54","spread":"176.11"},{"groupId":"OG003","value":"-51.4","spread":"229.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.21","spread":"41.91"},{"groupId":"OG001","value":"1.16","spread":"70.73"},{"groupId":"OG002","value":"-14.64","spread":"45.95"},{"groupId":"OG003","value":"25.82","spread":"80.29"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":54},"commonTop":["Vomiting","Nausea"]}}}